Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGY-1: Personalized 177Lu-PSMA-I&T in PSMA-expressing Cancers
NCT05896371Phase 2Not yet recruiting
- Sponsor
- CHU de Québec-Université Laval
- Start
- Mar 2028
- Primary completion
- Mar 2033
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of lutetium Lu 177 PSMA I&T in Metastatic Prostate Cancer (mPC), solid tumor, sponsored by CHU de Québec-Université Laval. Planned start Mar 2028; status: not yet recruiting.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
Metastatic Prostate Cancer (mPC)solid tumor
Beyond the preview
Go deeper on NCT05896371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896371.